Oncolytics Biotech Inc

Financials

Cash from operating activities —————-20.11 M — Cash from investing activities —————-6 000 — Cash from financing activities —————14.12 M — Free cash flow —————-20.12 M —

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

ONCY

Financials

Oncolytics Biotech Inc

Notícias

H.C. Wainwright reitera classificação de compra para ações da Oncolytics Biotech

Oncolytics agenda reunião com FDA sobre caminho regulatório para medicamento contra câncer anal

Oncolytics Biotech conclui primeira etapa de redomiciliação para Colúmbia Britânica

Oncolytics launches phase 2 colorectal cancer study REO 033

Oncolytics to wind down GOBLET study, focus on U.S. registration

Ações da Oncolytics Biotech disparam após FDA conceder designação Fast Track

Oncolytics Biotech stock soars after FDA grants Fast Track Designation

Pelareorep-atezolizumab mostra resultados promissores no câncer anal

Pelareorep-atezolizumab shows promising results in anal cancer

Oncolytics Biotech plans to shift incorporation from Canada to Nevada

Oncolytics Biotech files patent application to extend pelareorep protection

Oncolytics Biotech expands GI cancer advisory board with three experts